Fig. 3

Time (months) to first new patient randomised for each STAMPEDE research comparisons. The ‘original comparisons’ (pale blue) opened slowly, deliberately activating few centres in the first 18 months, during a phase to understand acceptability of randomisation and any key toxicity signals. The ‘M1|RT comparison’ (green) only applied to a subset of patients defined by whether they have metastatic disease (~60%). The ‘tE2 comparison’ (gold), which started most recently, also applies only to a subset of patients, defined strictly by any treatment to which they have been exposed between diagnosis and randomisation